CN115969788A - A spray-type epidemic prevention product (quasi-drug) for blocking respiratory virus infection and its preparation method - Google Patents
A spray-type epidemic prevention product (quasi-drug) for blocking respiratory virus infection and its preparation method Download PDFInfo
- Publication number
- CN115969788A CN115969788A CN202111206502.6A CN202111206502A CN115969788A CN 115969788 A CN115969788 A CN 115969788A CN 202111206502 A CN202111206502 A CN 202111206502A CN 115969788 A CN115969788 A CN 115969788A
- Authority
- CN
- China
- Prior art keywords
- spray
- respiratory tract
- virus
- epidemic prevention
- quasi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention belongs to a kind of medical equipment of health and epidemic prevention articles (or quasi-medicine), and is characterized by that it uses spray mode to block the virus propagated through respiratory tract from inward infection and outward transmission through nasal cavity and oral cavity so as to provide an epidemic prevention method and selection for medical health.
Description
Technical Field
The present invention belongs to a kind of medical equipment of sanitary and epidemic-prevention articles (or quasi-drugs), and is characterized by that it uses spray to block the transmission of virus which can be transmitted and infected by using respiratory tract, and can block the inward infection and outward transmission of virus.
Background
The virus transmitted and infected by using the respiratory tract is a frequently-occurring infectious disease, has wide infectious groups, multiple virus types and variations and high epidemic prevention cost, and brings great influence on social production and life.
Faced with this popularity and keeping up with this variability, great pressure is placed on medicine and medicine. The invention is suitable for preventing such infectious events and provides a method and an option for medical health.
Disclosure of Invention
The technical problem to be solved by the invention is as follows:
viruses transmitted through the respiratory tract are blocked by aerosol means from infecting intranasally and orally (upper respiratory tract) and spreading externally.
When leaving the infected area and entering the uninfected area, the use of the blocking spray can prevent the possible infection risk from spreading outwards; when entering the infected area from the uninfected area, the blocking spray can prevent the infection of the infected area through the nasal cavity and the upper respiratory tract.
The method is easy to implement, flexible and convenient.
The invention has low dosage, low drug property and low cost.
The technical scheme of the invention is as follows:
1. the invention relates to an in-vivo virus inhibitor and a virus transmission blocker in spray form, which are similar to alcohol for in-vitro disinfection.
2. The spray blocker comprises medicaments with in vitro antivirus effect and in vivo safety, a mucosa improver and a slow release agent.
3. The spray blocker of the invention comprises an oral spray and a nasal spray which are used simultaneously, and is not excluded to be used as a flushing agent.
4. The spray blocker is used at regular intervals, or before entering a public environment and before entering a safe environment.
The invention, taking the new coronavirus as an example, does not exclude other viruses that are transmitted through the nasal cavity and the upper respiratory tract. The drugs and concentrations varied according to the different viruses.
In the present invention, taking new coronavirus as an example, redesivir (Remdesivir), greater than 0.66 μ M; or and, ivermectin (Ivermectin), greater than 2.0 μ M; acetylcysteine, less than 0.3 g/day; azelastine hydrochloride, less than 0.56 mg/day; or, and, vitamin e; or and, collagen; a sustained release agent; a solvent; or and, water.
Compared with the prior art, the invention has the advantages that:
1. the present invention differs from vaccines and therapeutics in the way that viral epidemics are eliminated.
2. The invention focuses on the prevalence of diseases and is not a treatment for diseases.
3. The invention prevents both infection and transmission to others.
4. The present invention and method are easy and convenient to implement.
5. The invention applies the preparation substances to the surface in the body, and consumes a small amount of the preparation.
6. The invention has low toxicity and side effect.
7. The invention has low total cost for individuals and society.
8. The invention is useful for animals.
9. The invention has wide application range and can be used for various viruses transmitted by respiratory tracts.
10. The invention has the advantages of less experimental limit, low cost and clear result.
Claims (9)
1. The feature of claim 1 is that a spray for inhibiting virus, changing the environment of internal surface mucous membrane and blocking virus transmission in nasal cavity and oral cavity (upper respiratory tract administration) by spraying.
2. The method according to claim 1, wherein the transmission of viruses transmitted via the respiratory tract, such as neocoronavirus, SARS, MARS, avian influenza, influenza virus, etc., is blocked.
3. The method of claim 1, wherein the spread of the virus outward and the infection inward are blocked.
4. The method of claim 1, wherein the upper respiratory infection is a viral inhibitor present on an in vivo surface that is metastatic to the lower respiratory tract.
5. A method according to claim 1, characterized in that the viral inhibiting substances are sprayed nasally and buccally, without excluding rinsing and without treatment.
6. A spray formulation according to claim 2, characterized in that it comprises an in vitro virucidally effective and in vivo safe medicament, a mucosa-improving agent, a slow-release agent, a solvent.
7. The spray according to claim 2, characterized in that it comprises a substance which alters the mucosal properties of the nasal cavity and the upper respiratory tract.
8. The method of claim 2, wherein, in the case of the novel coronavirus, reidesvir (Remdesivir), is greater than 0.66 μ M; or/and, ivermectin (Ivermectin), greater than 2.0 μ M; or/and, acetylcysteine, less than 0.3 g/day; or/and, azelastine hydrochloride, less than 0.56 mg/day; or/and, vitamin e; or/and, collagen; a sustained release agent; or/and, a solvent; or/and, water.
9. The method of claim 3, wherein the method is used for humans and for animals.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111206502.6A CN115969788A (en) | 2021-10-16 | 2021-10-16 | A spray-type epidemic prevention product (quasi-drug) for blocking respiratory virus infection and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111206502.6A CN115969788A (en) | 2021-10-16 | 2021-10-16 | A spray-type epidemic prevention product (quasi-drug) for blocking respiratory virus infection and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115969788A true CN115969788A (en) | 2023-04-18 |
Family
ID=85961072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111206502.6A Pending CN115969788A (en) | 2021-10-16 | 2021-10-16 | A spray-type epidemic prevention product (quasi-drug) for blocking respiratory virus infection and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115969788A (en) |
-
2021
- 2021-10-16 CN CN202111206502.6A patent/CN115969788A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070054834A1 (en) | Quaternary ammonium halides for treatment of infectious conditions | |
| BR0108730A (en) | System, device and method for administering a drug, mouthpiece of a drug delivery device, device for administering multiple unit doses of a drug, methods for preparing a drug delivery system and a drug formulation and for treatment of a patient who needs multiple doses of a drug, drug formulation and multiparticulates | |
| JP2023526547A (en) | Certain drug systems, methods, and uses for reducing viral replication in airway mucosa | |
| JP2010285436A5 (en) | ||
| EA022840B1 (en) | Pharmaceutical composition, kit, use thereof and method for prophylactics and treatment of a symptom, condition or disease associated with infection by an influenza virus | |
| RU2728939C1 (en) | Using dalargin for producing agents for treating covid-19 coronavirus infection | |
| MX2021010834A (en) | Compound and method for the prevention of transmission of influenza virus. | |
| CA2504872A1 (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
| US20230226100A1 (en) | Cyclodextrin based anti-microbial therapy | |
| CN116056714A (en) | Method for preventing coronavirus and/or respiratory fusion virus infection | |
| RU2006129278A (en) | PHARMACEUTICAL COMPOSITION | |
| CA2650980A1 (en) | Statins for the treatment of viral influenza infections | |
| CN115969788A (en) | A spray-type epidemic prevention product (quasi-drug) for blocking respiratory virus infection and its preparation method | |
| Joseph et al. | State-of-the-art nanotechnology-based drug delivery strategies to combat covid-19 | |
| EP4181933B1 (en) | Antiviral pharmaceutical composition comprising at least one sulphated polysaccharide | |
| Wutzler et al. | Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports | |
| WO2021207271A1 (en) | Organoselenide glutathione peroxidase mimetics for the treatment of inflammatory pulmonary disorders | |
| WO2006113835A2 (en) | Method of stimulating immune response in certain individuals | |
| EP4218726A1 (en) | Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method | |
| WO2017174593A1 (en) | Novel antiviral compositions for the treatment of influenza | |
| Waghchaure et al. | A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT | |
| TWI836258B (en) | Method of prophylaxis of coronavirus and/or respiratory syncytial virus infection | |
| Hamad | Minocycline superior to chloroquine phosphate as COVID-19 treatment | |
| EP3906934A1 (en) | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |